Literature DB >> 21901179

PURLs: statins for patients with nonalcoholic fatty liver?

Mari Egan1, Shailendra Prasad.   

Abstract

Although physicians often avoid prescribing statins for patients with nonalcoholic fatty liver, their use has been found to reduce cardiovascular morbidity and mortality- and to lower liver enzymes.

Entities:  

Year:  2011        PMID： 21901179      PMCID： PMC3183966     

Source DB:  PubMed          Journal:  J Fam Pract        ISSN： 0094-3509            Impact factor:   0.493


  11 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

Review 2.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

Review 3.  Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.

Authors:  F Angelico; M Burattin; C Alessandri; M Del Ben; F Lirussi
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

Authors:  Leon A Adams; James F Lymp; Jenny St Sauver; Schuyler O Sanderson; Keith D Lindor; Ariel Feldstein; Paul Angulo
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

5.  Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians.

Authors:  Fadi S Rzouq; Michael L Volk; Hilana H Hatoum; Siva K Talluri; Rajasekhara R Mummadi; Gagan K Sood
Journal:  Am J Med Sci       Date:  2010-08       Impact factor: 2.378

6.  Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.

Authors:  Vasilios G Athyros; Konstantinos Tziomalos; Thomas D Gossios; Theodora Griva; Panagiotis Anagnostis; Konstantinos Kargiotis; Efstathios D Pagourelias; Eleni Theocharidou; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Lancet       Date:  2010-11-23       Impact factor: 79.321

7.  Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

Authors:  Cecilia Söderberg; Per Stål; Johan Askling; Hans Glaumann; Greger Lindberg; Joel Marmur; Rolf Hultcrantz
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

8.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.

Authors:  Kittichai Promrat; David E Kleiner; Heather M Niemeier; Elizabeth Jackvony; Marie Kearns; Jack R Wands; Joseph L Fava; Rena R Wing
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

Review 9.  Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.

Authors:  Chin Hee Kim; Zobair M Younossi
Journal:  Cleve Clin J Med       Date:  2008-10       Impact factor: 2.321

10.  Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.

Authors:  Eugen Florin Georgescu; Marius Georgescu
Journal:  J Gastrointestin Liver Dis       Date:  2007-03       Impact factor: 2.008
View more
  2 in total

1.  Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.

Authors:  Pooja Malhotra; Costica Aloman; Aparna Ankireddy; Hani Khadra; Kohtaro Ooka; Ravinder K Gill; Seema Saksena; Pradeep K Dudeja; Waddah A Alrefai
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-08-03       Impact factor: 4.052

2.  Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease.

Authors:  Mohammad J Alkhatatbeh; Lisa F Lincz; Rick F Thorne
Journal:  Exp Ther Med       Date:  2016-02-10       Impact factor: 2.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.